Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
WEDNESDAY, APRIL 29, 2026
08:30 - 09:30
REGISTRATION AND MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
AI-DISCOVERED PEPTIDES: A NON-PHARMACEUTICAL BREAKTHROUGH FOR WEIGHT MANAGEMENT
Zohar Barbash
Lembas

Zohar Barbash

Lembas

  • Detailing an AI platform finding naturally derived bioactive peptides for metabolic support
  • Recapping DIO rat outcomes and early human signals supporting weight loss efficacy
  • Positioning food-based peptides as a safe, sustainable path beyond synthetic obesity drugs
10:05 - 10:10
Q&A SESSION ON AI-DISCOVERED PEPTIDES FOR WEIGHT MANAGEMENT
10:10 - 10:35
GLOBAL PREVENTION OF DIABETES
Madhu Malo
Stapgen LLC

Madhu Malo

Stapgen LLC

  • Linking diabetes risk to intestinal alkaline phosphatase deficiency and endotoxin detoxification processes
  • Reviewing mouse evidence that bovine IAP supplementation prevents hyperglycemia in diabetic models
  • Outlining how therapeutic-grade BIAP could be evaluated as a scalable diabetes-prevention approach
10:35 - 10:40
Q&A SESSION ON DIABETES PREVENTION
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
Sponsored By MADRIGAL PHARMACEUTICALS
11:00 - 11:30
PANEL DISCUSSION ON THE SILENT EPIDEMIC OF METABOLIC SYNDROME
Speaker ImageSpeaker ImageSpeaker ImageSpeaker Image
  • Uncovering barriers to early detection and prioritizing underestimated modern drivers to scale effective metabolic syndrome interventions
  • Clarifying pivotal causes, diagnosing diabetes vulnerability, and applying practical prevention steps to stop progression from metabolic syndrome
  • Reframing lifestyle design and coaching to overcome the limits of medical advice and exercise for durable population-scale reversal

| CVS Healthspire Payor Solutions | Moderator

| Lembas

| Stapgen LLC

| The Erring Human

11:30 - 11:55
REDEFINING SURGICAL BOUNDARIES: AI IN COLORECTAL SURGERY FOR PATIENTS WITH METABOLIC CHALLENGES
Nandita Mahajan
Montefiore Medical Center

Nandita Mahajan

Montefiore Medical Center

  • Advancing AI, 3D printing, and machine learning integration for colorectal surgery in obesity care
  • Enhancing patient understanding and shared decision-making when metabolic risk shapes surgical options
  • Modernizing training with simulation and AI-guided planning for complex colorectal procedures
  • Safeguarding equitable AI adoption by addressing bias, transparency, and clinical accountability
11:55 - 12:00
Q&A SESSION ON AI IN COLORECTAL SURGERY FOR METABOLIC RISKS
12:00 - 13:30
NETWORKING LUNCH AND VISITING THE OBESITY MEDICINE EXHIBITION
13:30 - 13:55
FINANCING AND CORPORATE TRANSACTIONS ENVIRONMENT IN METABOLIC MEDICINE: CURRENT TRENDS AND OUTLOOK FOR THE FUTURE
Stanislav Glezer
Outcome Capital, LLC

Stanislav Glezer

Outcome Capital, LLC

  • Assessing how 2025 financing headwinds slow early-stage metabolic R&D and academic spinout formation
  • Tracing the shift from late-stage deals to earlier licensing and partnering by major pharma groups
  • Anticipating global impacts as China and Asian biotechs challenge U.S. and European deal dominance
13:55 - 14:00
Q&A SESSION ON FINANCING TRENDS IN METABOLIC MEDICINE
14:00 - 14:25
THE MIND/BODY PROBLEM – METABOLIC SYNDROME AND COGNITIVE DECLINE
Steve Winshel
Paraxis

Steve Winshel

Paraxis

  • Clarifying the strong links between metabolic dysfunction and cognitive impairments
  • Underscoring complications due to the late detection of cognitive decline in patients
  • Showcasing innovative early detection tools to slow or prevent brain changes
  • Integrating mind–body approaches to address both metabolic and cognitive issues
14:25 - 14:30
Q&A SESSION ON LINKING METABOLISM AND BRAIN HEALTH
14:30 - 14:55
DIGITAL INNOVATION IN METABOLIC PSYCHIATRY
Megan Kirk Chang
University of Oxford

Megan Kirk Chang

University of Oxford

  • Exploring staged metabolic care with ketogenic diets and GLP-1-supported lifestyle interventions in psychiatry
  • Delivering AI-enabled ketogenic insights and lifestyle guidance with monitoring and real-world data
Noah Wayne
NexJ Health Inc.

Noah Wayne

NexJ Health Inc.

  • Prioritizing key lifestyle components and evidence to embed digital metabolic care in psychiatry
  • Tailoring clinical workflows and research to integrate AI-enabled lifestyle platforms at scale
14:55 - 15:00
Q&A SESSION ON DIGITAL METABOLIC PSYCHIATRY IN PRACTICE
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:30 - 15:55
THE MIND–METABOLISM LOOP
Eric Headlee
Arise Elite Longevity

Eric Headlee

Arise Elite Longevity

  • Presenting chronic psychological stress as the most systematically undertreated upstream driver of metabolic dysfunction and neurodegeneration — and why current treatment models keep arriving too late
  • Mapping the Mind–Metabolism Loop — HPA axis dysregulation, glucose instability, vascular damage, blood–brain barrier compromise — and the intervention points where the cycle can be broken
  • Reframing methylation and detoxification pathway variants as stress-sensitive risk amplifiers — a precision medicine opportunity hiding in plain sight
  • Introducing a Resolution–Regulation–Optimization framework that sequences intervention from root cause forward, with implications for therapeutic development, clinical trial design, and patient outcomes
15:55 - 16:00
Q&A SESSION ON THE MIND-METABOLISM LOOP IN METABOLIC DISEASES
16:00 - 16:25
ENABLING DEVICE SOLUTIONS FOR UNMET NEEDS IN BIOTHERAPIES
Asmita Khanolkar
SMC® Ltd.

Asmita Khanolkar

SMC® Ltd.

  • Spotlighting novel methods for drug-device delivery optimization and assessment
  • Debuting an autoinjector simulator to evaluate pharmacokinetics and pharmacodynamics
  • Accelerating early evaluation and speed to clinic for biologics with unique needs
16:25 - 16:30
Q&A SESSION ON ENABLING DEVICE SOLUTIONS IN BIOTHERAPIES
16:30 - 16:55
WHY LONG-TERM WEIGHT LOSS FAILS: A METABOLIC FEEDBACK LOOP PERSPECTIVE BEYOND CALORIES
Samir Kohli
The Erring Human

Samir Kohli

The Erring Human

  • Examining metabolic and adaptive feedback loops that drive weight regain despite initial loss
  • Explaining why calorie-focused and compliance-led models ignore hormonal and behavioral dynamics
  • Operationalizing systems-based metabolic principles into durable fasting-informed weight plans
16:55 - 17:00
Q&A SESSION ON METABOLIC FEEDBACK LOOPS IN WEIGHT LOSS
17:00 - 18:00
NETWORKING DRINKS RECEPTION
Day 2 :
THURSDAY, APRIL 30, 2026
09:00 - 09:30
MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
ENSURING ACCESS AND SUPPORT IN OBESITY CARE
Sansei Fowler
CVS Health

Sansei Fowler

CVS Health

  • Expanding patient access to obesity treatments through optimal payer coverage strategies
  • Coordinating care models for GLP-1 therapy to provide comprehensive support for improved outcomes
  • Forecasting future trends in obesity treatment by analyzing drug pipelines and the role of PBMs in care
10:05 - 10:10
Q&A SESSION ON ACCESS AND SUPPORT IN OBESITY TREATMENT
10:10 - 10:35
NA-931: AN ORAL QUADRUPLE RECEPTOR AGONIST FOR WEIGHT LOSS WITHOUT MUSCLE LOSS
Lloyd Tran
Biomed Industries, Inc.

Lloyd Tran

Biomed Industries, Inc.

  • Describing the mechanism of action of this oral quadruple receptor agonist
  • Summarizing topline Phase 1 and Phase 2 clinical trial results on the safety and efficacy of NA-931
  • Reporting significant weight loss with no muscle loss or major GI-related adverse events
10:35 - 10:40
Q&A SESSION ON NA-931 AND ADVANCES IN WEIGHT MANAGEMENT
10:40 - 11:05
TRANSFORMING OBESITY RESEARCH WITH METABOLIC TRACER TECHNOLOGIES
Dan Bolt
Metabolic Solutions

Dan Bolt

Metabolic Solutions

  • Tracking patient fat synthesis, oxidation, and energy use directly with metabolic tracer assays
  • Using tracer-based case studies that add valuable endpoints in metabolic disease trials
  • Implementing tracer protocols into preclinical and clinical workflows without disrupting operations
  • Aligning tracer platforms with GLP standards and regulators to speed adoption in obesity research
11:05 - 11:10
Q&A SESSION ON METABOLIC TRACERS IN OBESITY RESEARCH
11:10 - 11:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:30 - 11:55
METABOLIC ARCHITECTURE: THE PHYSIOLOGY OF A HIGH-RETENTION CLINICAL ECOSYSTEM
Naomi Parrella
Classic Care MD | Zero Longevity Science | Advanced Medical Models

Naomi Parrella

Classic Care MD | Zero Longevity Science | Advanced Medical Models

  • Harmonizing pharmacotherapy, surgery, and lifestyle in a metabolic loop that preserves lean mass
  • Standardizing care with the ABCDE framework so teams deliver consistent metabolic plans at scale
  • Achieving a solvent, high-reliability clinic model with >65% retention and employer-aligned growth
11:55 - 12:00
Q&A SESSION ON HIGH-RETENTION METABOLIC CARE MODELS
12:00 - 12:25
BRIDGING CLINICAL EFFICACY AND SCALABLE ENTERPRISE IMPLEMENTATION: eMed's GLP-1 PROGRAM
Dyan Hes
eMed

Dyan Hes

eMed

  • Specifying a digitally integrated, employer-based GLP-1 program with structured telehealth oversight
  • Orchestrating prescribing, titration, safety checks, and at-home biomarker testing in obesity care
  • Visualizing de-identified BMI, biomarker, and engagement trends for employers on secure dashboards
12:25 - 12:30
Q&A SESSION ON SCALABLE GLP-1 CARE DELIVERY MODELS
12:30 - 12:55
FINDING THE RARE IN THE MASS: USING RWE TO IDENTIFY RARE METABOLIC PHENOTYPES IN THE GLP-1 ERA
Sanjay Ahuja
Regal Intel

Sanjay Ahuja

Regal Intel

  • Detecting GLP-1 non- and super-responders in RWE to uncover hidden rare metabolic phenotypes
  • Profiling claims and EHR histories to flag GLP-1 non-responders suitable for disease screening
  • Validating GLP-1 use in select rare conditions with RWE to support orphan indications and pricing
  • Constructing synthetic control arms from historical data to speed trials in rare indications
12:55 - 13:00
Q&A SESSION ON RWE FOR RARE METABOLIC PHENOTYPES
13:00 - 13:25
AI-DRIVEN LIFESTYLE INTERVENTION IN THE NHS POPULATION
Niall Colwell
RediCare Control

Niall Colwell

RediCare Control

  • Scaling AI-driven lifestyle coaching across NHS populations to reduce type 2 diabetes risk
  • Reporting real-world outcomes that show how engagement shifts prevalence trends in T2D
  • Modeling curve impact, where 10% engagement bends growth, and 20% can flatten it
13:25 - 13:30
Q&A SESSION ON AI-DRIVEN NHS LIFESTYLE INTERVENTIONS
13:30 - 13:45
FEEDBACK AND RAFFLE DRAW
13:45 - 15:00
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.